Under one in 10 patients eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it releases its first guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to this class of drugs.
Based on forecasts, over two billion could be obese by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be addressed with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can help people shift significant body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Even in the present most favorable case, the production of such drugs could only cover about 100 million people – under 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to expand access, through strategies such as licensing agreements.
A patent on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Work
The injections replicate a biological compound to reduce digestion speed, reduce hunger and enhance satiety so people eat less.
Individuals commonly start to lose weight in the initial weeks of starting on the once-weekly jabs.
Evidence indicates users may put most of the weight back on after a year of discontinuing the drug, because their normal appetite come back.
To be carrying excess weight raises your risk for contracting medical conditions, such as diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight affects people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
